



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

HL

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/619,347	07/14/2003	F. Paul Silverman	VAL6131P0591US	6353

7590 10/06/2004

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER  
Citicorp Center, Suite 3800  
500 West Madison Street  
Chicago, IL 60661-2511

EXAMINER

CLARDY, S

ART UNIT

PAPER NUMBER

1616

DATE MAILED: 10/06/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/619,347	SILVERMAN ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	S. Mark Clardy	1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 10 November 2003.  
 2a) This action is **FINAL**.      2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-18 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1-18 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
     Paper No(s)/Mail Date 10/20/03.

4) Interview Summary (PTO-413)  
     Paper No(s)/Mail Date. \_\_\_\_\_.  
 5) Notice of Informal Patent Application (PTO-152)  
 6) Other: \_\_\_\_\_.

Art Unit: 1616

Claims 1-18 are pending in this application which claims benefit of US Provisional Application 60/433,830, filed December 16, 2002.

Applicants' claims are drawn to herbicidal compositions and methods comprising a photosystem II (PSII) inhibiting herbicide<sup>1</sup> and a salicylate (SA) or other Systemic Acquired Resistance (SAR) inducer<sup>2</sup>.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 5, 6, 7, 9, and 18 are rejected under 35 U.S.C. 102(a), and (b) as being anticipated by Klepper<sup>3</sup>.

Klepper teaches the combination of SA with PSII inhibiting herbicides, i.e., atrazine, bentazon, cyanazine, diuron, metribuzin, norea, phenmedipham, and prometryn (p. 175) in aqueous solution, with the test concentration of the PSII herbicide at 300 ppm or 0.03% (p. 174, "Materials", 2<sup>nd</sup> para). One of the stated goals was to determine whether SA could act as a synergist (p. 174, 2<sup>nd</sup> col, lines 1-5). Klepper concludes that while SA does act as a synergist (p. 178), other salicylates may be more persistent and therefore more practical or effective (p. 179).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

---

<sup>1</sup> Claim 2: atrazine, bentazon

<sup>2</sup> Claims 10-16: hydroxypicolinic acid, acibenzolar (=BTH), dichloroisonicotinic acid, (di)chlorosalicylic acid compounds

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teachings of Klepper and Ryals et al<sup>4</sup>.

Klepper has been discussed above. This reference does not appear to address the SAR activating characteristic of SA.

Ryals et al teach that SA, acibenzolar (BTH), and other compounds are known activators of SAR. One of ordinary skill in the art of plant growth regulating compounds would be motivated to substitute the SA of Klepper with a compound such as acibenzolar because Ryals et al teach their equivalent activity in plants as SAR activators.

Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have combined SA or other SAR inducers such as acibenzolar, with PSII inhibiting herbicides such as atrazine or bentazon, because Klepper teaches such compositions, and because SA and acibenzolar are both known signaling molecules which are useful for stimulating SAR in plants. The teachings of the prior art would suggest to the ordinary artisan that the biochemical signaling characteristics of SA and acibenzolar are interchangeable.

No unobvious or unexpected results are noted; no claim is allowed.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later

---

<sup>3</sup> Klepper. "Synergistic Levels of Nox Emissions from Soybean Leaves Caused by a Combination of Salicylic Acid and Photosynthetic Inhibitor Herbicides". *Pesticide Biochemistry and Physiology*. 32:173-179. 1988.

<sup>4</sup> Ryals et al. "Systemic Acquired Resistance ". *The Plant Cell*. 8:1809-1819. October 1996.

invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to S. Mark Clardy whose telephone number is 571-272-0611. The examiner can normally be reached on 7:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on 571-272-0887. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



S. Mark Clardy  
Primary Examiner  
Art Unit 1616

October 1, 2004